71 published reports across 35 sub-industries — how the market prices the sector, which comparables set the range, and what has actually transacted.
The deeper cut: the landscape, the valuation spread, the situations that follow from it and the precedent transaction record.
Sector ReportSep 28, 2026Health Care
This sector report shows how platform model, recurring revenue quality and workflow position align with valuation in Life Sciences Tools and Instruments, using public comparables and precedent transactions. Written for investors, executives and boards evaluating sector positioning as of September 2026.
Life Sciences Tools and Instruments · 21 pages · Free to read
Sector ReportSep 28, 2026Health Care
This report prices nine life sciences research reagent and supply companies on forward revenue, splits the sector into four valuation groups, and reviews recent reagent-business acquisitions. For corporate development and finance teams tracking sector valuation and M&A.
Life Sciences Research Reagents and Supplies · 21 pages · Free to read
Sector ReportSep 28, 2026Health Care
This report covers the Contract Research Organizations sector: 11 public companies, forward revenue multiples, growth and margin cohorts, and nine disclosed precedent transactions. Built for owners, boards and acquirers weighing where service-capacity and partnership-platform economics are priced today.
Contract Research Organizations (CRO) · 21 pages · Free to read
Sector ReportSep 28, 2026Health Care
A sector outlook on the eleven listed Contract Development and Manufacturing names, covering public-market valuation on EV/Revenue (CY2027E), precedent transactions and strategic implications for owners, acquirers and boards assessing capacity and capability positioning as of September 2026.
Contract Development and Manufacturing (CDMO) · 21 pages · Free to read
Sector ReportSep 28, 2026Health Care
This sector outlook covers seven clinical-stage Therapeutic Discovery Platform companies, comparing forward valuation on EV/Revenue (CY2027E), precedent M&A terms since 2019, and the capital-allocation choices platform owners face next.
Therapeutic Discovery Platforms · 21 pages · Free to read
Sector ReportSep 28, 2026Health Care
This report maps the antibody and protein therapeutics sector into three EV/Revenue valuation tiers, explains what separates the top and bottom of the range, and reviews nine recent acquisitions. Built for boards, management teams and corporate development functions weighing capital and partnering decisions.
Antibody and Protein Therapeutics · 22 pages · Free to read
Sector ReportSep 28, 2026Health Care
A sector-level valuation and M&A review of regenerative medicine, covering implants, instrumentation, therapeutics and adjacent models. Written for owners, management teams and boards assessing where profit visibility and precedent deal pricing sit across the sector as of September 2026.
Regenerative Medicine · 20 pages · Free to read
Sector ReportSep 28, 2026Health Care
A sector outlook on Cell and Gene Therapies covering public market valuation, precedent M&A and strategic drivers across the 47-company approved universe. Built for investors, management teams and corporate development leads assessing where value sits between platform developers and commercial-stage supply.
Cell and Gene Therapies · 22 pages · Free to read
Sector ReportSep 28, 2026Health Care
A NeuraCap sector outlook on rare and orphan disease therapeutics, covering the public company landscape, valuation drivers, precedent transactions and strategic implications for owners, management teams and boards weighing pipeline durability against commercial execution.
Rare and Orphan Disease Therapeutics · 23 pages · Free to read
Sector ReportSep 28, 2026Health Care
This report maps the ophthalmic therapeutics screen — 14 companies split between clinical-stage programme owners and one sterile-supply business — against EV/Revenue (CY2026E) and nine precedent transactions, for corporate development teams and boards assessing sector value.
Ophthalmic Therapeutics · 20 pages · Free to read
Sector ReportSep 28, 2026Health Care
This sector report examines Neurology and CNS Therapeutics across clinical-stage biotech, specialty neurology and diversified franchises, comparing public valuations and precedent transactions by business model. For executives and boards weighing capital allocation and portfolio strategy in CNS therapeutics.
Neurology and CNS Therapeutics · 21 pages · Free to read
Sector ReportSep 28, 2026Health Care
This report reviews the Immunology and Inflammation Therapeutics sector as of September 28, 2026, covering public-market valuation on EV/Revenue (CY2026E), segment mix, valuation drivers and precedent transactions.
Immunology and Inflammation Therapeutics · 20 pages · Free to read
Sector ReportSep 28, 2026Health Care
This sector outlook maps the Oncology Therapeutics public universe on EV/Revenue (CY2027E), reviews precedent transactions, and sets out strategic implications for owners, management teams and boards navigating clinical-stage and commercial-stage assets.
Oncology Therapeutics · 22 pages · Free to read
Sector ReportSep 28, 2026Health Care
A sector-wide valuation map of 85 Biotechnology companies, covering EV/Revenue benchmarks, growth and margin drivers, situation analysis, and recorded M&A transactions. Built for boards, management teams and capital allocators sizing where a company sits in the range.
Biotechnology · 23 pages · Free to read
Sector ReportSep 28, 2026Health Care
A sector outlook on Specialty and Branded Pharmaceuticals, comparing EV/Revenue (CY2027E) valuation across pipeline, hybrid-portfolio and diversified-platform businesses, plus precedent transaction pricing. For owners, management teams and boards assessing revenue durability and portfolio choices.
Specialty and Branded Pharmaceuticals · 23 pages · Free to read
Sector ReportSep 28, 2026Health Care
A sector outlook on Generic and Non-Prescription Drugs, covering public market valuation across complex generics, branded off-patent and consumer self-care segments, precedent transactions, and the growth-margin dynamics separating the top and bottom of the range.
Generic and Non-Prescription Drugs · 21 pages · Free to read
Sector ReportSep 28, 2026Health Care
A sector benchmarking report on six listed Health Care Workforce Services companies, comparing valuation across learning and competency platforms, hospital-based physician practice management and diversified staffing. For corporate development and board audiences tracking valuation drivers and deal structure.
Health Care Workforce Services · 20 pages · Free to read
Sector ReportSep 28, 2026Health Care
A sector outlook on Pharmaceuticals covering diversified majors, development-stage therapeutics and specialty manufacturers — for owners, management teams and boards assessing where earnings durability sits against valuation across the public peer set and the precedent transaction record.
Pharmaceuticals · 22 pages · Free to read
Sector ReportSep 28, 2026Health Care
This report shows how public and transaction values for health care data and analytics companies differ across data platforms, services-led models and adjacent health care businesses, using consensus EV/Revenue estimates and disclosed deal terms as of September 2026.
Health Care Data and Analytics · 22 pages · Free to read
Sector ReportSep 28, 2026Health Care
This sector outlook maps 11 Genetic and Screening Services companies across reference testing and adjacent business models, comparing EV/Revenue valuation, growth cohorts and precedent transactions. Built for owners, management teams and boards assessing where growth converts into durable, collectible revenue.
Genetic and Screening Services · 20 pages · Free to read
Sector ReportSep 28, 2026Health Care
A sector outlook on Digital Health and Telehealth, covering how platforms, care delivery and adjacent models price on EV / Revenue (CY2027E), the growth-multiple relationship across the rated universe, and the precedent transaction record.
Digital Health and Telehealth · 23 pages · Free to read
Sector ReportSep 28, 2026Health Care
A sector outlook on Home Health and Long-Term Care, covering forward valuation, growth and margin drivers, precedent transactions and strategic implications. Built for owners, operators and boards weighing where earnings durability separates the peer set, as of September 2026.
Home Health and Long-Term Care · 22 pages · Free to read
Sector ReportSep 28, 2026Health Care
A sector outlook on Clinical Laboratory Services covering scaled lab networks, specialty diagnostics and adjacent models. It benchmarks 22 approved companies on EV/Revenue (CY2027E), reviews precedent transactions, and sets out strategic implications for owners, operators and boards assessing growth, reimbursement
Clinical Laboratory Services · 22 pages · Free to read
Sector ReportSep 28, 2026Health Care
A sector outlook on Outpatient and Specialty Care Services, covering business models, forward valuation, precedent transactions and strategic implications for owners, operators and boards navigating growth, profitability and capacity economics across the peer set.
Outpatient and Specialty Care Services · 22 pages · Free to read
What moved, what companies announced and what changed in M&A, every two weeks.
Bi-Weekly UpdateSep 28, 2026Health Care
This bi-weekly report tracks price moves, company actions and transaction activity across Life Sciences Tools and Instruments for September 14–28, 2026. It gives operators, acquirers and advisors a fast, evidence-based read on what changed, who moved, and what the trailing deal record implies for pricing.
Life Sciences Tools and Instruments · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
Bi-weekly update on the Contract Research Organizations sector covering price moves, company announcements and the M&A transaction record for September 14–28, 2026, for investors, operators and advisers tracking CRO platform and services economics.
Contract Research Organizations (CRO) · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
A bi-weekly update on the Contract Development and Manufacturing (CDMO) sector covering public market moves, major company actions and M&A activity for September 14–28, 2026, for operators, acquirers and advisers tracking sector pricing and deal activity.
Contract Development and Manufacturing (CDMO) · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
A bi-weekly scorecard of the Life Sciences Research Reagents and Supplies sector, tracking share-price moves, company news and precedent transaction activity for owners, operators, acquirers and advisors following the space.
Life Sciences Research Reagents and Supplies · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
A bi-weekly read on Therapeutic Discovery Platforms covering price moves, disclosed catalysts and the transaction record across September 14–28, 2026, built for operators, acquirers and advisors tracking the space.
Therapeutic Discovery Platforms · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
This bi-weekly report tracks public market moves, major announcements and M&A activity across 58 antibody and protein therapeutics companies for September 14–28, 2026, built for investors, operators and advisors monitoring clinical catalysts and valuation benchmarks in the sector.
Antibody and Protein Therapeutics · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
A bi-weekly read on Regenerative Medicine public-market moves, company news and M&A activity for September 14–28, 2026, built for operators, acquirers and advisors tracking sector-defining regulatory and transaction signals.
Regenerative Medicine · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
A bi-weekly read on cell and gene therapies covering share-price moves, major news catalysts and M&A activity from September 14–28, 2026, for operators, acquirers and advisors tracking platform-level versus program-level value in the sector.
Cell and Gene Therapies · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
This bi-weekly report tracks public market moves, major news catalysts and M&A activity across 39 covered rare and orphan disease therapeutics companies for September 14–28, 2026, giving operators, acquirers and advisers a fast read on what moved, why, and what transacted.
Rare and Orphan Disease Therapeutics · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
A bi-weekly update on Ophthalmic Therapeutics covering stock moves, clinical and regulatory catalysts, and M&A activity across 12 covered names for the two weeks of September 14–28, 2026. Built for operators, acquirers and advisors tracking the sector's readout calendar and deal record.
Ophthalmic Therapeutics · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
This bi-weekly report tracks public-market moves, major news catalysts and M&A activity across Neurology and CNS Therapeutics for September 14–28, 2026, for investors, operators and advisors who need to see which company disclosures moved prices and what closed.
Neurology and CNS Therapeutics · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
A bi-weekly read on Immunology and Inflammation Therapeutics: public market moves, major news catalysts, and M&A activity for September 14–28, 2026, built for operators, acquirers, and advisors tracking sector-relative performance and deal activity.
Immunology and Inflammation Therapeutics · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
A bi-weekly read on Oncology Therapeutics covering public market moves, major regulatory and clinical catalysts, and M&A activity across 47 covered names for September 14–28, 2026. Built for operators, acquirers and advisors tracking where evidence and price are diverging in the sector.
Oncology Therapeutics · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
This biweekly report tracks biotechnology share-price moves, company announcements and M&A activity for September 14–28, 2026, giving operators, acquirers and advisors a fast read on what changed, who moved, what transacted and why it matters.
Biotechnology · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
This bi-weekly update tracks price moves, catalysts and M&A activity across 23 covered Specialty and Branded Pharmaceuticals names for September 14–28, 2026, built for investors, operators and advisors monitoring sector repricing and deal flow.
Specialty and Branded Pharmaceuticals · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
This bi-weekly update tracks share-price moves, major approvals and M&A activity across generic and non-prescription drug companies for September 14–28, 2026, giving operators, acquirers and advisers a clear read on what changed and what it means.
Generic and Non-Prescription Drugs · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
This bi-weekly report tracks public market moves, major news and the M&A reference set across Health Care Workforce Services for September 14–28, 2026. It is built for operators, acquirers and advisors tracking sector-specific evidence rather than broad market direction.
Health Care Workforce Services · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
A bi-weekly roundup of pharmaceutical sector share-price moves, company news and M&A activity for September 14–28, 2026, built for operators, acquirers and advisers tracking commercial-stage and development-stage names across the space.
Pharmaceuticals · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
This bi-weekly update tracks share-price moves, company news and M&A activity across nine covered Health Care Data and Analytics names for September 14–28, 2026, giving operators, acquirers and advisors a fast read on what changed and what it means.
Health Care Data and Analytics · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
A bi-weekly briefing on Genetic and Screening Services covering September 14–28, 2026: which covered names moved, what companies announced on evidence and capacity, and what the M&A transaction record showed. Built for operators, acquirers and advisors tracking regulatory, clinical and deal activity across the sector.
Genetic and Screening Services · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
A bi-weekly read on Digital Health and Telehealth: what moved share prices, what companies announced, and what changed in the M&A record between September 14–28, 2026. Built for operators, acquirers and advisors tracking evidence-based signals across a 14-name covered set.
Digital Health and Telehealth · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
A bi-weekly read on Home Health and Long-Term Care: which stocks moved, what companies announced, what transacted, and what it means for operators, acquirers and advisors tracking the sector.
Home Health and Long-Term Care · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
This bi-weekly update tracks share-price moves, company announcements and M&A activity across 20 covered Clinical Laboratory Services names for September 14–28, 2026, for operators, acquirers and advisors following coverage, coding and reimbursement developments in the sector.
Clinical Laboratory Services · 7 pages · Free to read
Bi-Weekly UpdateSep 28, 2026Health Care
A bi-weekly briefing on outpatient and specialty care services, tracking public market moves, major company events and M&A activity across 16 covered names. Built for corporate development, investor relations and advisory teams tracking the sector's disclosure, capacity and labour-supply signals.
Outpatient and Specialty Care Services · 7 pages · Free to read
Company valuation reports run the same method against a single business, public or private.